Phenotypic screening in cancer drug discovery — past, present and future
The DOI matches its Crossref record; 181 of the 182 references it cites were found in a registry or an index.
Abstract
There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. Given that oncology is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncology drug discovery by analysing the origins of all new small-molecule cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clinical development. Although the majority of these drugs originated from target-based discovery, we identified a significant number whose discovery depended on phenotypic screening approaches. We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes. However, technical and biological advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phenotypic screening is a strategy that analyzes biology-associated (phenotypic) effects in given models such as animals, cells, or organisms to help identify the targets of candidate drugs.25,50”
From Drug repurposing for cancer therapy (2024) · cites this paper as [25]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Cited by
Items 401–500 of 523
Cho, E., Baird, S. D., & Eccles, K. M. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04165-2 · Cited by 2
“Cell Painting has predominantly been used in the drug discovery space (Swinney and Anthony 2011; Moffat et al. 2014; Li and Xia 2019; Fredin Haslum et al. 2024) and, more recently, for hazard screening of environmental chemicals.”
Liu, X., Lu, Y., Chen, Q., Yang, M., Li, S., Sun, H., Liu, X., Yan, J., Liangning, L., Xiang, N., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.005 · Cited by 1
“…, phenotypic screening approach remains a crucial strategy for identifying, validating, and developing new anticancer drugs with optimal molecular action mechanisms 23 , especially for chemo-refractory and drug-resistant tumors 24,25 where improved therapeutic options are urgently needed 26,27 .”
Li, J., Lu, R., Tan, Y., Liang, P., Liu, B., Gu, S., Liu, H., & Yao, X. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.009 · Cited by 1
“Additionally, this methodology can aid in target deconvolution by identifying the binding partner of compounds whose biological activity was originally observed through phenotypic screening 65 .”
Schneider, S. A., D’Amora, P., Evans, S. S., Kent, P. M., Stockwell, T. M., Bakaya, V. S., Bernard, P. J., Francisco, F. R., Torres, L., Henry, J. S., et al. (2026) · Cancers · doi:10.3390/cancers18111744 · Cited by 1
“Human tumor primary culture analyses for the selection of drugs and combinations have gained attention as new technologies allow investigators to interrogate individual patient tumors to explore novel agents and combinations [25–27].”
Xia, X. (2018) · Springer eBooks · doi:10.1007/978-3-319-90684-3_19 · Cited by 1
Lenci, E., Innocenti, R., Biagioni, A., Menchi, G., Bianchini, F., & Trabocchi, A. (2016) · Molecules · doi:10.3390/molecules21101405 · Cited by 1
In Silico Tools to Leverage Rational Drug Design and Development in LMICs
Bucci, P., & Cardama, G. A. (2024) · Frontiers in computational chemistry · doi:10.2174/9789815179033124070003 · Cited by 1
Cancer phenomics research hotspots and development trends: a bibliometric analysis from 2000 to 2023
Chen, S., Liu, J., Tang, N., & Zeng, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01710-w · Cited by 1
Cell-Based Assays Using Derived Human-Induced Pluripotent Cells in Drug Discovery and Development
Ross, J. A., & Mandenius, C. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4530-7_1 · Cited by 2
Case I: 3DMed: An R&D Platform for Personalised Precision Anti-cancer Drugs
Zhu, X. (2017) · Management for professionals · doi:10.1007/978-981-10-5388-7_1 · Cited by 1
Movia, D., & Prina‐Mello, A. (2018) · InTech eBooks · doi:10.5772/intechopen.69447 · Cited by 2
“imatinib, trastuzumab, crizotinib and vemurafenib) [2], various nanomedicine products [3, 4] have been approved for clinical use in recent times, for more effective and safer cancer treatment.”
BackgroundHigh Content Screening of Small Molecule Modulators Targeting Heat Shock Response Pathway
Zhang, D., & Zhang, B. (2018) · Heat shock proteins · doi:10.1007/978-3-319-90725-3_8 · Cited by 1
Usón, P. L. S., Wagner, J., Corpa, M. V. D. N., Coelho, I. M., Nagourney, R. A., & Yamaguchi, N. H. (2019) · SAGE Open Medical Case Reports · doi:10.1177/2050313x19838739 · Cited by 1
Phenotype screenings of drugs for combination therapy against multidrug resistance
Mohammed, A., & Alghamdi, O. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820576-1.00011-4 · Cited by 1
Qudoos, A., Almani, S., Mangi, K. H., Hafeez, M., & Shah, S. F. A. (2020) · Quaid-e-Awam University Research Journal of Engineering Science & Technology · doi:10.52584/qrj.1802.03 · Cited by 1
Raynaud, F. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812784-1.00009-8 · Cited by 1
Tamuli, K. J., Narzary, B., Saikia, S., & Bordoloi, M. (2023) · ACS Omega · doi:10.1021/acsomega.3c03129 · Cited by 1
Zhang, H., Ma, X., & Lin, Z. (2023) · International Symposium on Artificial Intelligence for Medicine Sciences (ISAIMS) · doi:10.1145/3644116.3644315 · Cited by 1
Force et spécificité du criblage pour des molécules bioactives au CMBA-Grenoble
Barette, C., Soleilhac, E., Charavay, C., Cochet, C., & Fauvarque, M. (2015) · médecine/sciences · doi:10.1051/medsci/20153104017 · Cited by 1
Lead Generation for Challenging Targets
Wan, J., Dou, D., Song, H., Cheng, X. W. X., & Li, J. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677047.ch10 · Cited by 1
Magalhães, L. G. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.76.2019.tde-28082019-113629 · Cited by 1
Tanabe, K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.16.440090 · Cited by 1
“An alternative to target-based screening is phenotype-based drug screening, which has recently undergone a revival and re-evaluation (Johannessen et al., 2014; Moffat et al., 2014, 2017; Mullard, 2015; Wagner and Schreiber, 2016; Zheng et al., 2013).”
MethodDeJarnette, C. A. (2020) · doi:10.21007/etd.cghs.2020.0518 · Cited by 2
Blonder, J., Kaczmarczyk, J. A., Roberts, R. R., Luke, B. T., Chan, K. C., Wagoner, C. M. V., Felder, R. A., Saul, R. G., & Colantonio, S. (2020) · Research Square · doi:10.21203/rs.3.rs-72194/v1 · Cited by 1
Identification and Development of Therapeutics for COVID-19.Preprint
Rando, H. M., Wellhausen, N., Ghosh, S., Lee, A. J., Dattoli, A. A., Hu, F., Byrd, J. B., Rafizadeh, D. N., Lordan, R., Qi, Y., et al. (2021) · PubMed Central · Cited by 2
TOLEDO: Accelerated Maestro GUI molecular dynamics simulationsPreprint
Carmena‐Bargueño, M., Martínez-Cortés, C., Banegas‐Luna, A. J., & Pérez‐Sánchez, H. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-2qsc4 · Cited by 1
Kumar, P., Josa‐Culleré, L., Jackson, T., Bataille, C. J. R., Vyas, P., Milne, T. A., & Russell, A. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.06.572546 · Cited by 1
“30,31 Gaining insight on the target and MoA of small molecules often relies on high-quality tool compounds, which can support the challenging task of distinguishing between on-target and off-target effects.”
BackgroundLessons learned from phenotypic drug discovery efforts
Swinney, D. C. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2442741 · Cited by 1
“This strategy was termed the mechanism informed PDD by John Moffat in his 2014 paper [17].”
Predicting Targeted Cancer TherapeuticsPreprint
Wise, A. S., & Çobanoğlu, M. C. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/057901
“On the other hand, de novo drug discovery requires high-throughput screening over millions of chemicals and even the most relevant of these assays are conducted on monotypic cell lines in test tubes – missing critical aspects of relevance to human disease such as heterogeneity and microenvironment [25].”
BackgroundMultiobjective Optimization of Biological and Physical Properties in Drug Discovery
Gleeson, M. P., & Montanari, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12315-7 · Cited by 1
Identification of Mitotic Blockers by Phenotypic Screening of a Clinical Compound Library
Son, Y. H., Park, C. H., & Choi, S. U. (2016) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.10999 · Cited by 1
Pharmaceutical Industry Performance
Swinney, D. C. (2017) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-50042-3_1
Morrison, J. S., & Hageman, M. J. (2017) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-50042-3_14
Rawat, K., Shard, A., Jadhav, M., Gandhi, M., Anand, P., Purohit, R., Padwad, Y. S., & Sinha, A. K. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.11.015
Investigation of Porcupine Bezoar Extract combined with Electroporation on HeLa Cell
Azizulkarim, A. H., Mahadi, M. A. A. M., Jamil, A., Nadzlin, T. I. T., Ibrahim, T. N. T., Hamdan, S., Baba, S., & Wahab, R. A. (2018) · IEEE International Conference on Control System, Computing and Engineering · doi:10.1109/iccsce.2018.8685005
“An oncology has develop into the largest therapeutic area in the pharmaceutical filed in terms of the total number of project, clinical trials and research and development allocate [2].”
BackgroundWan, X., O’Neill, E., & Ebner, D. V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-444-64046-8.00306-2
Elucidating Target Biology and Drug Mechanism of Action Across Human Cell‐Based Model Systems
Dawson, J. C., & Carragher, N. O. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527818242.ch7
Cancer Research in the “Chemical Biology” Section of the Journal Molecules
Corson, T. W. (2020) · Molecules · doi:10.3390/molecules25225275
“Moreover, chemical biology methods have led to countless other research tools used in cancer laboratories, from phenotypic small molecule screening methods [5], to chemical probes such as bromodomain inhibitor JQ1 [6], to workhorse assays such as EdU S-phase labeling [7], to imaging tools for use at the molecular to o…”
BackgroundLongden, J., Robin, X., Engel, M., Ferkinghoff‐Borg, J., Kjær, I., Horak, I. D., Pedersen, M. W., & Linding, R. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3185112
Shabajee, P., Gaudeau, A., Legros, C., Dorval, T., & Stéphan, J.-P. (2021) · médecine/sciences · doi:10.1051/medsci/2021013 · Cited by 1
Inference of Computational Models of Alternative Polyadenylation and Splicing
Leung, M. K. K. (2018) · TSpace (University of Toronto)
The activity of nybomycin against mycobacterium tuberculosis.
Niehaus, A. J. (2018) · ResearchSpace (University of KwaZulu-Natal)
Stereoselective Synthesis of β-Glycinamide Ribonucleotide
Ngu, L., Ray, D., Watson, S. S., Beuning, P. J., Ondrechen, M. J., & O'Doherty, G. A. (2022) · Molecules · doi:10.3390/molecules27082528
Zanders, E. D. (2015) · Wiley eBooks · doi:10.1002/9781118849842.ch1
Structured Approach to the Development of New Cancer Drugs Using DrosophilaPreprint
Nezhad, A. F. (2022) · doi:10.22541/au.166811184.48566276/v1
Kalra, R. S., Singh, S., Munshi, A., & Bariwal, J. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1106610
“It comprises elements of biology and chemistry for developing novel drugs/ small molecules demonstrating potent anti-cancer efficacy (1).”
BackgroundTissue-engineered Cancer Models in Drug Screening
Cao, R., Fomina, A., & McGuigan, A. P. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166013-00415
Structure-based Drug Discovery and Advances in Protein Receptor Crystallography
Congreve, M., & Marshall, F. H. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781782621423-00045
Pecenin, M. F. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2021.tde-14012022-182511
Pan, Z., & Liang, P. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_663 · Cited by 2
Natural Products as Cytotoxic Agents
Pullman, M. K., León, F., & Cutler, S. J. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc216.pub2
Ji, W., Byun, W. S., Lu, W., Zhu, X., Donovan, K. A., Dwyer, B. G., Che, J., Yuan, L., Abulaiti, X., Corsello, S. M., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202308292
Corey, E. J., & Wu, Y. (2023) · Wiley eBooks · doi:10.1002/9781394207145.ch11
de Souza, S. F. D. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.82.2021.tde-10112022-160330
Study of Cytotoxic Responses of Anticancer Drug Cyclophosphamide
Mohale, V. B., Bharade, V. S., Wagh, V. S., Katariya, K. A., & Khan, N. (2023) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-14213
Suehnholz, S. P., Nissan, M. H., Zhang, H., Kundra, R., Nandakumar, S., Lu, C., Carrero, S., Dhaneshwar, A., Fernandez, N. C., Xu, B. W., et al. (2024) · doi:10.1158/2159-8290.24988631
Self-citationMachine learning applications in cancer genomics
El-Charif, O., Schwartz, R. S., Yuan, Y., & Tao, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822000-9.00006-9
What does it take to make progress in a disease?Preprint
Ringel, M. S., Dethier, J., Davitt, M. J., Denslow, M., Fowler, R., Hasenfuss, S. C., & Schulze, U. (2024) · medRxiv · doi:10.1101/2024.02.27.24303441
“26,27 Furthermore, the history of drug R&D is replete with examples of phenotypic discovery for which targets were never identified, 28,29,30,31,32 or for which the sequence of activities happened in virtually every permutation of the archetype.”
Design strategies for protein-protein interaction inhibitors using non-natural amino acids
Tököli, A. (2023) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.11678
Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep LearningPreprint
Ocasio, B. A., Hu, J., Stathias, V., Martinez, M. J., Burnstein, K. L., & Schürer, S. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.15.623715
Old Drugs: Confronting Recent Advancements and Challenges
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6198-0
Multiobjective optimization of biological and physical properties in drug discovery
Gleeson, M. P., & Montanari, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00014-5
Drug Resistance and Novel Targets for Cancer Therapy
Mohite, P. B., Puri, A. V., Munde, S. V., Patil, R., & Singh, S. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-96-4959-4_7
Modern Computational Intelligence Based Drug Repurposing for Cancer
Budha, R. R., Khan, N., Khan, S., Attar, E. S., & Rao, G. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_23
Zhu, L., & Luo, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.25.665130
In-Silico Pharmacology, Methods and Applications for Drug Design and Discovery: A Review
Bala, M., Sapna, S., Dogra, M., Sharma, H., & Savita, S. (2025) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2025.00038 · Cited by 1
A Review on Drug Design: Strategies, Advances, and Future Directions
Kodalkar, S. B., Parase, S. G., Gorad, K. R., Shirkule, R. V., & Abasaheb, K. S. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-28653
Sharma, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5500999
High-throughput screening in microbial drug development
Mishra, S. S., Chauhan, A., Rastogi, S., & Bhardwaj, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33032-2.00010-1
Zhu, F., Wang, Q., Zheng, X., Chen, R., Liu, C., Xiang, L., He, J., & Dai, Y. (2025) · Protein and Peptide Letters · doi:10.2174/0109298665404512251021101809
Leung, G. H. D., Pun, F. W., Naumov, V., Gennert, D. G., Kamya, P. R. N., Aliper, A., Ren, F., & Zhavoronkov, A. A. (2026) · Springer eBooks · doi:10.1007/978-3-031-98022-0_3 · Cited by 1
Gong, T., Jin, Y., Zhu, H., Cheng, Z., Fang, H., Xu, N., Zhao, F., Liu, Y., & Chen, P. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117715
Pruteanu, L.-L., Béquignon, O. J. M., Broersma, Y., Bender, A., Ibrahim, S. M., Bailey, D. S., & Westerman, B. A. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag030
Self-citationPrimer: Drug discovery and patient-derived organoids
Boonekamp, K. E., & Boutros, M. (2026) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2026.100579 · Cited by 1
Nouvelles méthodes électrochimiques pour le criblage d’inhibiteurs de transcétolases
Aymard, C. (2018) · theses.fr (ABES) · doi:10.70675/47be351bzc9a1z4e08z8502zead21e001030 · Cited by 2
Ariey-Bonnet, J. (2020) · theses.fr (ABES) · doi:10.70675/63ceaea1ze673z40c3z9960zed4c40d88ea9
Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725
Criblage de petites molécules d'intérêt thérapeutique et recherche de leur mécanisme d'action
Rozié, A. (2020) · theses.fr (ABES) · doi:10.70675/cfe93a65zdad1z4f4fzb5e3z4c2daf8ea474
High throughput assessment of viability in 2D and 3D cell culture
Doffe, F., Leduc, M., Deng, X., Kroemer, G., & Kepp, O. (2026) · Methods in cell biology · doi:10.1016/bs.mcb.2026.04.009
BLAST, FASTA, and String Algorithms
Xia, X. (2026) · Springer eBooks · doi:10.1007/978-3-032-18842-7_1
Impact of regularization methods and outlier removal on unsupervised sample classification
Heckman, C. A. (2026) · BMC Bioinformatics · doi:10.1186/s12859-026-06539-4
“These methods are particularly ill-suited for projects where workers want to recognize phenotypes relevant to drug development but lack a detailed knowledge of the mechanisms causing the disease state [6–9].”
Advances in cancer drug discovery integrated with computational approaches
Sinha, A., Santoshi, S., Chourasia, M., Kumar, J., & Bansal, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44181-3.00002-3
Osada, H. (2026) · Bulletin of the Chemical Society of Japan · doi:10.1093/bulcsj/uoag062
Time-resolved phenotypic profiling maps EGFR and c-Met trafficking signatures
Tanabe, K. (2026) · Scientific Reports · doi:10.1038/s41598-026-61308-w
“Nonetheless, nominal MOA labels should be treated as supportive annotations rather than definitive mechanistic assignments 59,61 .”
Mandal, S., Choudhary, R., Laskar, A. A. I. P., Chawla, S., & Konkimalla, V. B. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119789
Ai Driven Approaches in Drug Target Identification
khan, A., Siddiqui, F., Aggarwal, P., & Anas, M. (2026) · Innovations in Sustainable Technologies and Computing · doi:10.1007/978-3-032-22830-7_37
Wang, P., Wu, H., Zhang, J., Zhang, J., Zhuge, Y., Wu, F., & Yan, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119197
Cao, Y., Wu, Y., Li, Y., Li, S., Youssif, B. G. M., Du, J., & Ma, L. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118776
Li, S., Huang, J., Yan, Y., Jaspers, R. T., Pathak, J. L., Xiao, Y., & Zhang, Q. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.08.043
“In contrast, phenotypic drug screening (PDS) circumvents this limitation by directly utilizing cellular or tissue-level phenotypic alterations as screening endpoints, thereby enhancing the discovery potential of first-in-class therapeutics [164].”
Zhang, Y., Bai, Y.-X., Tian, G. G., Zhang, B., Lu, D., Yao, Q., Tian, W., Wei, X., Yang, J.-T., Xiong, Z., et al. (2026) · Advanced Science · doi:10.1002/advs.77835
“…that the system was built on certain mechanisms identical across plants and animals such as cytoskeleton and topoisomerase, our system also has some features of mechanism-informed phenotypic drug discovery (MIPDD), which is categorized by conducting phenotypic assays for specific targets [ 46 ].”
Harmych, S. J., & Singh, B. (2026) · Cancer Medicine · doi:10.1002/cam4.72305
Jeschke, A., Musa, J., Cidre‐Aranaz, F., Ohmura, S., & Gul, S. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5587-0_12
Matsunaga, K., Honda, K., Ali, M., Hameed, A., Inoue, R., Tsuno, T., Kin, T., Shapiro, A. M. J., Obinata, H., Kondoh, Y., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.09.019
Metadata
- Authors
- Moffat, J. G., Rudolph, J., & Bailey, D.
- Affiliations
- Genentech (US)
- Corresponding author
- Moffat, John G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-07-18
- Volume
- 13
- Issue
- 8
- Pages
- 588-602
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2123059506
- Semantic Scholar
- 1042a4c884176fac046b7c6751c953ed949f8066
- Cited by
- 507
- References
- 182
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 43 · 2023: 30 · 2022: 36 · 2021: 48 · 2020: 45 · 2019: 48 · 2018: 52 · 2017: 56 · 2016: 42 · 2015: 39 · 2014: 3
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- phenotypic screening, anticancer drug discovery, anticancer drug development, small molecule anticancer agents, FDA-approved anticancer drugs, target-based drug discovery, cytotoxicity, mitotic arrest
- MeSH terms
- Antineoplastic Agents, Drug Screening Assays, Antitumor, Forecasting, Humans, Neoplasms, Phenotype, History, 20th Century, History, 21st Century, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.